Exelixis (EXEL) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 4:05 PM EDT- Total Revenues of $259.5 Million, Cabozantinib Franchise Revenues of $178.7 Million -
- GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.25 -
- Conference Call and Webcast Today at 5:30 PM Eastern Time -
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Exelixis continued to execute on... More
